Lonza's New GS System™ Medium and Feed Platform Reaches 10g/L

- Customers realize higher product yields, improved cellular metabolism, a more reliable process, and a lower total cost of goods
- Medium and feed platform is free from royalty and license fees
- Includes GS CHO-specific chemically defined, animal component-free (CDACF) cell culture medium, feed base powders and supplements

Basel, Switzerland, 28 June 2011 – Lonza is launching a new cell culture medium and feed platform for the GS Gene Expression System™ that achieves product yields up to 10g/L. The CDACF “Version 8” platform, together with the GS System™, forms the backbone of Lonza's robust and reliable mammalian production technology.

“Lonza understands the need to innovate and help our growing GS customer base realize immediate cost savings during early-phase development,” said Janet White, Head of Lonza Development Services. “We are very confident that this latest improvement to our GS System™ will be a significant advancement for mammalian bioproduction.”

The Version 8 platform incorporates GS-CHO-specific CDACF cell culture medium, feed base powders and supplements and will be globally manufactured and supplied by Lonza's media production facilities. Developed with Lonza's extensive experience in biological manufacturing, the CDACF Version 8 platform realizes higher product yields and improved cellular metabolism to achieve a more robust process.

Lonza has also successfully used the CDACF Version 8 medium and feed platform with DHFR-CHO cell lines. The Version 8 platform is available to all holders of the GS Gene Expression System™. Lonza will continue to support all media customers including those currently implementing the Version 6 protein-free system and the Version 7 CDACF system.

For more information, please contact one of our experts:
+1 201 316 9200  North America
+41 61 316 8111  Europe

About the GS Gene Expression System™
The GS Gene Expression System™, which is owned and licensed by Lonza, is used for the production of therapeutic recombinant proteins and monoclonal antibodies. Nearly 100 biotechnology and pharmaceutical companies and over 75 academic laboratories worldwide are successfully using the GS Gene Expression System™, which has established itself as the industry standard. This system is characterized by its speed and ease of use. In addition, the higher yielding cell lines provide cost-efficient production of therapeutic proteins.

About Lonza
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers’ needs from research to final
product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2010, the company had sales of CHF 2.680 billion. Further information can be found at www.lonza.com.

For further Information:

Lonza Group Ltd
Head of Corporate Communications
Dominik Werner
Tel +41 61 316 8798
Fax +41 61 316 9798
dominik.werner@lonza.com

Lonza Group Ltd
Investor Relations
Dirk Oehlers
Tel +41 61 316 8540
Fax +41 61 316 9540
dirk.oehlers@lonza.com

Lonza Group Ltd
Media Relations
Melanie Disa
Tel +1 201 316 9413
Fax +1 201 696 3533
melanie.disa@lonza.com